{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:33:23Z","timestamp":1789990403203,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>National Comprehensive Cancer Network (NCCN) 2019 Guidelines recommend universal germline (GL) testing for patients (pts) with pancreatic cancer (PC), given germline mutations (gMut) can occur at a similar rate irrespective of an individual\u2019s family history of cancer. Molecular analysis of tumors in those with metastatic disease is also recommended. We aimed to determine rates of genetic testing at our institution, factors associated with testing, and outcomes of those tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Frequency of GL and somatic testing was examined in pts diagnosed with non-endocrine PC, with &amp;gt;2 visits between June 2019 and June 2021 at the Mount Sinai Health System. The clinicopathological variables and treatment outcomes were also recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 149 pts met the inclusion criteria. Sixty-six pts (44%) underwent GL testing: 42 (28%) at time of diagnosis with the remainder later in treatment. The rate of GL testing increased every year: 33% (2019), 44% (2020), and 61% (2021). A family history of cancer was the only variable associated with the decision to perform GL testing. Eight pts (12% of pts tested) had pathological gMut: BRCA1 (1), BRCA2 (1), ATM (2), PALB2 (2), NTHL1 (1), both CHEK2 and APC (1). Neither gBRCA pt received a PARP inhibitor, all except one received first-line platinum. Ninety-eight pts (65.7%) had molecular tumor testing (66.7% of patients with metastases). Two pts with BRCA2 somatic mut did not have GL testing. Three pts received targeted therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Genetic testing based on provider discretion results in low rates of GL testing. Early results of genetic testing can have an impact on treatment decisions and trajectory of disease. Initiatives to increase testing are needed but must be feasible in real-world clinic settings.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyad044","type":"journal-article","created":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T17:26:17Z","timestamp":1679160377000},"page":"486-493","source":"Crossref","is-referenced-by-count":21,"title":["Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-3912","authenticated-orcid":false,"given":"Fionnuala","family":"Crowley","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Icahn School of Medicine , Mount Sinai Morningside West, New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Icahn School of Medicine , Mount Sinai Morningside West, New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rudshteyn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Icahn School of Medicine, Mount Sinai Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantej","family":"Sehmbhi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Icahn School of Medicine , Mount Sinai Morningside West, New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre J","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Mount Sinai Hospital , New York, NY , USA"},{"name":"Department of Hematology Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"issue":"1","key":"2023060913464996000_CIT0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2023060913464996000_CIT0002","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"12","key":"2023060913464996000_CIT0003","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"Pourshams","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2023060913464996000_CIT0004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/archinternmed.2010.63","article-title":"Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan)","volume":"170","author":"Arslan","year":"2010","journal-title":"Arch Intern Med"},{"issue":"10","key":"2023060913464996000_CIT0005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/annonc\/mdu276","article-title":"Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium","volume":"25","author":"Bosetti","year":"2014","journal-title":"Ann Oncol"},{"issue":"19","key":"2023060913464996000_CIT0006","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med"},{"issue":"18","key":"2023060913464996000_CIT0007","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"issue":"8","key":"2023060913464996000_CIT0008","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"7","key":"2023060913464996000_CIT0009","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.18632\/oncotarget.2972","article-title":"Molecular landscape of pancreatic cancer: implications for current clinical trials","volume":"6","author":"Heestand","year":"2015","journal-title":"Oncotarget"},{"issue":"20","key":"2023060913464996000_CIT0010","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","article-title":"Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2023060913464996000_CIT0011","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"issue":"23","key":"2023060913464996000_CIT0012","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"2023060913464996000_CIT0013","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","volume":"148","author":"Grant","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"2023060913464996000_CIT0014","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"issue":"13","key":"2023060913464996000_CIT0015","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023060913464996000_CIT0016","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3_suppl","key":"2023060913464996000_CIT0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2021.39.3_suppl.378","article-title":"Overall survival from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"39","author":"Golan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"2023060913464996000_CIT0018","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5.5","key":"2023060913464996000_CIT0019","first-page":"603","article-title":"NCCN Guidelines updates: pancreatic cancer","volume":"17","author":"Margaret","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"issue":"9","key":"2023060913464996000_CIT0020","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/genes11091098","article-title":"Building towards precision oncology for pancreatic cancer: real-world challenges and opportunities","volume":"11","author":"Wang","year":"2020","journal-title":"Genes"},{"issue":"15_suppl","key":"2023060913464996000_CIT0021","doi-asserted-by":"crossref","first-page":"10599","DOI":"10.1200\/JCO.2021.39.15_suppl.10599","article-title":"Compliance with germline testing in pancreatic cancer in a rural tertiary care hospital","volume":"39","author":"Travaline","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2023060913464996000_CIT0022","doi-asserted-by":"crossref","first-page":"e1982","DOI":"10.1002\/onco.13968","article-title":"Implementation of an embedded in-clinic genetic testing station to optimize germline testing for patients with pancreatic adenocarcinoma","volume":"26","author":"Walker","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"2023060913464996000_CIT0023","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1200\/OP.20.00678","article-title":"Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer","volume":"17","author":"Chittenden","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"2023060913464996000_CIT0024","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41436-020-0825-2","article-title":"The composition and capacity of the clinical genetics \u00adworkforce in \u00adhigh-income countries: a scoping review","volume":"22","author":"Dragojlovic","year":"2020","journal-title":"Genet Med"},{"issue":"8","key":"2023060913464996000_CIT0025","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41436-021-01162-5","article-title":"The 2019 US medical genetics workforce: a focus on clinical genetics","volume":"23","author":"Jenkins","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"2023060913464996000_CIT0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12913-018-2957-5","article-title":"Impact of a genetic counseling requirement prior to genetic testing","volume":"18","author":"Stenehjem","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"2023060913464996000_CIT0027","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41436-021-01262-2","article-title":"Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer","volume":"23","author":"Hamilton","year":"2021","journal-title":"Genet Med"},{"issue":"1","key":"2023060913464996000_CIT0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10689-022-00300-5","article-title":"Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake","volume":"22","author":"Ramsey","year":"2023","journal-title":"Fam Cancer"},{"issue":"3","key":"2023060913464996000_CIT0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajco.13334","article-title":"Mainstream consent programs for genetic counseling in cancer patients: a systematic review","volume":"17","author":"Scheinberg","year":"2021","journal-title":"Asia-Pac J Clin Oncol."},{"issue":"3","key":"2023060913464996000_CIT0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10689-021-00277-7","article-title":"Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer","volume":"21","author":"Bokkers","year":"2022","journal-title":"Fam Cancer"},{"issue":"2","key":"2023060913464996000_CIT0031","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cgh.2020.12.025","article-title":"Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer","volume":"20","author":"Dharwadkar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023060913464996000_CIT0032","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/EDBK_350292","article-title":"Genetic testing for all: overcoming disparities in ovarian cancer genetic testing.","volume":"42","author":"Frey","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"2023060913464996000_CIT0033","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1002\/cncr.34434","article-title":"Disparities in cancer genetics care by race\/ethnicity among pan-cancer patients with pathogenic germline variants","volume":"128","author":"Liu","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"2023060913464996000_CIT0034","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41391-021-00469-3","article-title":"Disparities in germline testing among racial minorities with prostate cancer","volume":"25","author":"Weise","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023060913464996000_CIT0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cancergen.2019.04.063","article-title":"Uptake of genetic testing for germline BRCA1\/2 pathogenic variants in a predominantly Hispanic population","volume":"235","author":"McGuinness","year":"2019","journal-title":"Cancer Genet"},{"issue":"4","key":"2023060913464996000_CIT0036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","article-title":"Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk","volume":"13","author":"Levy","year":"2011","journal-title":"Genet Med"},{"issue":"4","key":"2023060913464996000_CIT0037","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"2023060913464996000_CIT0038","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future \u00addirections diversity of enrollment in prostate cancer clinical trials","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6_Supplement_2","key":"2023060913464996000_CIT0039","doi-asserted-by":"crossref","first-page":"C043-C","DOI":"10.1158\/1538-7755.DISP19-C043","article-title":"Abstract C043: ethnic disparities among pancreatic cancer patients undergoing germline testing","volume":"29","author":"Velazquez","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2023060913464996000_CIT0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pan.2020.12.017","article-title":"Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application","volume":"21","author":"Sivapalan","year":"2021","journal-title":"Pancreatology"},{"issue":"7","key":"2023060913464996000_CIT0041","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/onco.13717","article-title":"Circulating tumor DNA-based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma","volume":"26","author":"Botrus","year":"2021","journal-title":"Oncologist"},{"issue":"20","key":"2023060913464996000_CIT0042","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.3390\/ijms21207651","article-title":"Current status of circulating tumor DNA liquid biopsy in pancreatic cancer","volume":"21","author":"Grunvald","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2023060913464996000_CIT0043","doi-asserted-by":"crossref","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","article-title":"Efficacy of \u00adplatinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","author":"Pokataev","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"2023060913464996000_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00115","article-title":"Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program","author":"Pishvaian","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"2023060913464996000_CIT0045","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med"},{"issue":"4","key":"2023060913464996000_CIT0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jval.2017.01.004","article-title":"A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer","volume":"20","author":"Eccleston","year":"2017","journal-title":"Value Health"},{"issue":"2","key":"2023060913464996000_CIT0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/0003-4819-155-2-201107190-00002","article-title":"Strategies to identify the Lynch syndrome among patients with colorectal cancer: a \u00adcost-\u00adeffectiveness analysis","volume":"155","author":"Ladabaum","year":"2011","journal-title":"Ann Intern Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/486\/50514483\/oyad044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/486\/50514483\/oyad044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T21:19:31Z","timestamp":1701897571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/486\/7080524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,18]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad044","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,3,18]]}}}